Yuliet Mora Amador, MD
Family Medicine · Houston, TXNPI 1285981290
Payments from drug & device makers
Across 437 payments — averaging $4799.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$2M
- Merck$59K
- AstraZeneca$52K
- AbbVie$557
- Bayer$470
- Novo Nordisk$455
- plus $3K from 30 others
What the payments were for
- Food & beverage$5,734100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 102 | $1,981,862 |
| Merck | 16 | $59,105 |
| AstraZeneca | 65 | $52,182 |
| AbbVie(2 entities) | 42 | $557 |
| Bayer | 23 | $470 |
| Novo Nordisk | 22 | $455 |
| GSK | 30 | $428 |
| Lilly USA, LLC | 21 | $357 |
| Otsuka America Pharmaceutical, Inc. | 17 | $315 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $238 |
| Amgen(2 entities) | 11 | $186 |
| Boehringer Ingelheim | 12 | $176 |
| Exact Sciences | 6 | $125 |
| Sumitomo Pharma America, Inc. | 4 | $99 |
| Novartis | 5 | $85 |
| Astellas Pharma US Inc | 5 | $81 |
| Cranial Technologies, Inc | 6 | $80 |
| Paratek Pharmaceuticals, Inc. | 4 | $70 |
| Sanofi-aventis U.S. LLC | 3 | $64 |
| Amarin Pharma, Inc. | 3 | $61 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $55 |
| Hologic Sales And Service, LLC | 3 | $54 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $47 |
| Johnson & Johnson | 2 | $45 |
| Abbott | 2 | $42 |
| E.r. Squibb & Sons, L.L.C. | 1 | $32 |
| Genentech USA, Inc. | 2 | $28 |
| Redhill Biopharma Inc. | 2 | $27 |
| Organon | 1 | $24 |
| Cipher Pharmaceuticals US LLC | 1 | $21 |
| Lundbeck LLC | 1 | $16 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Mylan Specialty L.p. | 1 | $14 |
| Exeltis, USA Inc. | 1 | $13 |
| Dexcom, Inc. | 1 | $12 |
How this compares
$2,097,459 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 185 | $242,146 |
| OzempicSemaglutide | 94 | $154,872 |
| FarxigaDapagliflozin Propanediol | 100 | $130,163 |
| MounjaroTirzepatide | 77 | $111,998 |
| EliquisApixaban | 84 | $87,246 |
| GlyxambiEmpagliflozin/Linagliptin | 54 | $79,861 |
| RexultiBrexpiprazole | 37 | $57,461 |
| XareltoRivaroxaban | 44 | $49,380 |
| MyrbetriqMirabegron | 45 | $47,475 |
| TradjentaLinagliptin | 25 | $31,899 |
| VraylarCariprazine Hcl | 18 | $27,635 |
| TivicayDolutegravir Sodium | 12 | $27,234 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 38 | $26,900 |
| DescovyEmtricitabine/Tenofov Alafenam | 12 | $26,512 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $24,896 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Glyxambi, Tradjenta, Spiriva Respimat | $176 | $362,750279 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $52,182 | $157,063138 claims |
| Novo NordiskOzempic | $455 | $154,87294 claims |
| Lilly USA, LLCMounjaro, Trulicity | $357 | $135,09990 claims |
| PfizerEliquis | $1,981,862 | $87,24684 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $315 | $57,46137 claims |
| Johnson & JohnsonXarelto | $45 | $49,38044 claims |
| Astellas Pharma US IncMyrbetriq | $81 | $47,47545 claims |
| AbbVieVraylar | $557 | $27,63518 claims |
| GSKTrelegy Ellipta | $428 | $24,89630 claims |
| NovartisEntresto | $85 | $22,19120 claims |
| MerckJanuvia | $59,105 | $20,15016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Houston
- Lisa HollowayHouston$30.1M
- Veronica FragosoHouston$24.5M
- Bonnie ColvilleHouston$19.6M
- Oscar de ValleHouston$12.8M
- van TranHouston$11M
- Joe PouzarHouston$10.7M
- Aalia Al-BarwaniHouston$6.8M
- Terence ChangHouston$3.3M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.